Role of biotin-binding affinity in streptavidin-based pretargeted radioimmunotherapy of lymphoma

Bioconjugate Chemistry

Volumn 16, Issue 1, 2005, Pages 131-138

  Hamblett, Kevin J ^a,d   Press, Oliver W ^b,c   Meyer, Damon L ^c,d   Hamlin, Don K ^b   Axworthy, Don ^c   Wilbur, D Scott ^b   Stayton, Patrick S ^a  

^a University of Washington   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d SEATTLE GENETICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODIES; BINDING ENERGY; BIOMOLECULES; BLOOD; COENZYMES; MAMMALS; ONCOLOGY;

BINDING AFFINITIES; BIOCONJUGATES; BIOTIN BINDING; HUMAN SERUM ALBUMINS; IN-VIVO; LOCALISED; NUDE MICE; RADIOIMMUNOTHERAPY; STREPTAVIDIN; TUMOR SITE;

TUMORS;

BIOTIN; CD20 ANTIBODY; DRUG CARRIER; HUMAN SERUM ALBUMIN; IBRITUMOMAB TIUXETAN; IODINE 125; RITUXIMAB; STREPTAVIDIN; YTTRIUM 90;

ANIMAL EXPERIMENT; BINDING AFFINITY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG SPECIFICITY; DRUG TARGETING; IN VIVO STUDY; LYMPHOMA; MOUSE; NONHUMAN; NUDE MOUSE; RADIOACTIVITY; RADIOIMMUNOTHERAPY; SITE DIRECTED MUTAGENESIS;

ANIMALIA; MUS MUSCULUS;

EID: 12344275421     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc034049g     Document Type: Conference Paper

References (23)

1. Mclaughlin, P. (2002) Progress and Promise in the Treatment of Indolent Lymphomas. Oncologist 7, 217-225.
2. Witzig, T. E., Gordon, L. I., Cabanillas, F., Czuczman, M. S., Emmanouilides, C., Joyce, R., Pohlman, B. L., Bartlett, N. L., Wiseman, G. A., Padre, N., Grillo-Lopez, A. J., Multani, P., and White, C. (2002) Randomized Controlled Trial of Yttrium-90-Labeled Ibritumomab Tiuxetan Radioimmmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin's Lymphoma. J. Clin. Oncol. 20, 2453-2463.
3. 131-B1 (Anti-CD20) Antibody Therapy with Autologous Stem Cell Transplantation for Relapsed B Cell Lymphomas. Lancet 346, 336-340.
4. Axworthy, D. B., Reno, J. M., Hylarides, M. D., Mallett, R. W., Theodore, L. J., Gustavson, L. M., Su, F. M., Hobson, L. J., Beaumier, P. L., and Fritzberg, A. R. (2000) Cure of Human Carcinoma Xenografts by a Single Dose of Pretargeted Yttrium-90 with Negligible Toxicity. Proc. Natl. Acad. Sci. 97, 1802-1807.
5. Press, O. W., Corcoran, M., Subbiah, K., Hamlin, D. K., Wilbur, D. S., Johnson, T., Theodore, L., Yau, E., Mallett, R., Meyer, D. L., and Axworthy, D. (2001) A Comparative Evaluation of Conventional and Pretargeted Radioimmunotherapy of CD20-Expressing Lymphoma Xenografts. Blood 98, 2535-2543.
6. Schultz, J., Lin, Y., Sanderson, J., Zuo, Y., Stone, D., Mallet, R., Wilbert, S., and Axworthy, D. (2000) A tetravalent single-chain antibody-streptavidin fusion protein for pretargeted lymphoma therapy. Cancer Res. 60, 6663-6669.
7. Mock, D. M., and DuBois, D. B. (1986) A sequential, solid-phase assay for biotin in physiologic fluids that correlates with expected biotin status. Anal. Biochem. 153, 272-278.
8. Rusckowski, M., Fogarasi, M., Fritz, B., and Hnatowich, D. J. (1997) Effect of endogenous biotin on the applications of streptavidin and biotin in mice. Nucl. Med. Biol. 24, 263-268.
9. Klumb, L., Chu, V., and Stayton, P. S. (1998) Energetic Roles of Hydrogen Bonds at the Uriedo Oxygen Binding Pocket Streptavidin-Biotin Complex. Biochemistry 37, 7657-7663.
10. Baker, H. (1985), Assessment of Biotin Status: Clinical Implications. Ann. N. Y. Acad. Sci. 447, 129-132.
11. Shriver, B., Roman-Shriver, C., and Allred, J. B. (1993), Depletion and Repletion of Biotinyl Enzymes in Liver of Biotin-Deficiet Rats: Evidence of a Biotin Storage System. J. Nutr. 123, 1140-1149.
12. Baker, H., Frank, O., Chen, T., Feingold, S., DeAngelis, B., Baker, E. R. (1981) Elevated vitamin levels in colon adenocarcinoma as compared with metastatic liver adenocarcinoma from colon primary and normal adjacent tissue. Cancer 47, 2883-2886.
13. Hamblett, K. J., Kegley, B. B., Hamlin, D. K., Chyan, M., Hyre, D. E., Press, O. W., Wilbur, D. S., and Stayton, P. S. (2002), A Streptavidin-Biotin Binding System That Minimizes Blocking By Endogenous Biotin. Bioconjugate Chem. 13, 588-598.
14. Hyre, D. E., Le Trong, I., Freitag, S., Stenkamp, R. E., and Stayton, P. S. (2000) Ser45 plays an important role in managing both the equilibrium and transition state energetics of the streptavidin-biotin system. Protein Sci. 9, 878-885.
15. Chu, V., Freitag, S., Le Trong, I., Stenkamp, R. E., and Stayton P. S. (1998) Thermodynamic and structural consequences of flexible loop deletion by circular permutation in the streptavidin-biotin system. Protein Sci. 7, 848-859.
16. Chilkoti, A., Tan, P. H., and Stayton, P. S. (1995) Site-directed mutagenesis studies of the high-affinity streptavidin-biotin complex: contributions of tryptophan residues 79, 108, and 120. Proc. Natl. Acad. Sci. 92, 1219-1224.
17. Hylardies, M., Mallett, R. W., and Meyer, D. L. (2001) A Robust Method for the Preparation and Purification of Antibody/Streptavidin Conjugates. Bioconjugate Chem. 12, 421-427.
18. Huang, E. Z., and Rogers, Y. (1997) Competitive enzymatic assay of biotin. Methods Enzymol. 279, 304-308.
19. Weiden, P. L., Breitz, H. B., Press, O., Appelbaum, J. W., Bryan, J. K., Gaffigan, S., Stone, D., Axworthy, D., Fisher, D., and Reno, J. (2000) Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results. Cancer Biother. Radiopharm. 15, 15-29.
20. Green, N. (1975) Avidin. Adv. Protein Chem. 29, 85-133.
21. Wood, H. G. (1998) Biotin, in Vitamins: Fundamental Aspects in Nutrition & Health (Combs, G. F., Ed.) pp 349-363, Academic Press, San Diego,
22. 90Y-DOTA-biotin. J. Nucl. Med. 41, 131-140.
23. Sharkey, R. M., Karacay, H., Griffiths, G. L., Behr, T. M., Blumenthal, R. D., Mattes, M. J., Hansen, H. J., and Goldenberg, D. M. (1997) Development of a Streptavidin-Anti-Carcinoembryonic Antigen Antibody, Radiolabeled Biotin Pretargeting Method for Radioimmunotherapy of Colorectal Cancer. Studies in a Human Colon Cancer Xenograft Model. Bioconjugate Chem. 8, 595-604.